Cargando…
PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431468/ http://dx.doi.org/10.1097/01.HS9.0000851540.26904.c2 |
| _version_ | 1784780063666864128 |
|---|---|
| author | Di Folca, S. Marafioti, V. barbato, S. Avilia, S. Grimaldi, F. Severino, A. Picardi, M. Luciano, L. Battipaglia, G. Pane, F. |
| author_facet | Di Folca, S. Marafioti, V. barbato, S. Avilia, S. Grimaldi, F. Severino, A. Picardi, M. Luciano, L. Battipaglia, G. Pane, F. |
| author_sort | Di Folca, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431468 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94314682022-08-31 PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE Di Folca, S. Marafioti, V. barbato, S. Avilia, S. Grimaldi, F. Severino, A. Picardi, M. Luciano, L. Battipaglia, G. Pane, F. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431468/ http://dx.doi.org/10.1097/01.HS9.0000851540.26904.c2 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Di Folca, S. Marafioti, V. barbato, S. Avilia, S. Grimaldi, F. Severino, A. Picardi, M. Luciano, L. Battipaglia, G. Pane, F. PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE |
| title | PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE |
| title_full | PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE |
| title_fullStr | PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE |
| title_full_unstemmed | PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE |
| title_short | PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE |
| title_sort | pb2178: outcomes of reduced dose team (thiotepa, etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation for hodgkin and non-hodgkin lymphoma: a monocentric experience |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431468/ http://dx.doi.org/10.1097/01.HS9.0000851540.26904.c2 |
| work_keys_str_mv | AT difolcas pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT marafiotiv pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT barbatos pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT avilias pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT grimaldif pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT severinoa pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT picardim pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT lucianol pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT battipagliag pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience AT panef pb2178outcomesofreduceddoseteamthiotepaetoposidecytarabinemelphalanpriortoautologousstemcelltransplantationforhodgkinandnonhodgkinlymphomaamonocentricexperience |